Amarin Corp Plc (AMRN)

[Whalatane]

Jt. quick note
My issue with the design of R-IT was that they should have enrolled only Category 1 ( prior events ) patients .
That would have increased chances of success..

You are correct in that R-IT is designed to see if 4gms of Vascepa will reduce events in patients with median TG's of around 220 while LDL is controlled below 100.

Thanks to JF , Dude et al for providing notes from CC .
My quick observations .
MD obviously biased ...conflicts of interest ... so take his projections with at least a grain of salt .
So he says ...85% chance for a RRR of between 15-20%
Guess that means that all you thinking there will be a higher RRR then that ...only have a 15% chance of being right.
Kiwi